Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Multiple-Ascending-Dose Study of SRP-5051 in Duchenne Muscular Dystrophy
2019-000601-77Phase 2Terminated
- Sponsor
- Sarepta Therapeutics
- Start
- Jun 2019
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of Vesleteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Primary endpoint: Primary endpoints Part A. Started Jun 2019; status: terminated.
02
Drugs
Vesleteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2019-000601-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000601-77.